Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

TOPAZ: Single Arm, Open Label Phase 1b/2 Study of Tucatinib in COmbination With Pembrolizumab And TrastuZumab in Patients With HER2-Positive Breast Cancer Brain Metastases

NCT04512261 is registered in ClinicalTrials.gov with Reva Basho as lead sponsor.

NCT NCT04512261
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04512261 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
TOPAZ: Single Arm, Open Label Phase 1b/2 Study of Tucatinib in COmbination With Pembrolizumab And TrastuZumab in Patients With HER2-Positive Breast Cancer Brain Metastases
Lead sponsor
Reva Basho
Phase
Phase 1/2
Overall status
Withdrawn
Start date
June 1, 2022
Completion date
June 1, 2024
Enrollment
0 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

brain metastases, breast cancer, cns disease, her2-positive breast cancer